Evaluation of intracanal acetazolamide in late reimplanted rat teeth.

Autor:	Perin CP; Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil., Papalexiou V; Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil., Rodrigues Johann ACB; Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil., Ribeiro Mattos NH; Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil., Westphalen FH; Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil., Ditzel Westphalen VP; Departament of Endodontics Universidade Tuiuti do Paraná Curitiba, Paraná, Brazil.
Jazyk:	angličtina
Zdroj:	European journal of dentistry [Eur J Dent] 2017 Oct-Dec; Vol. 11 (4), pp. 417-421.
DOI:	10.4103/ejd.ejd_191_17
Abstrakt:	Objective: The aim of this study was to evaluate the use of acetazolamide combined with different agents as intracanal medication in late reimplanted rat teeth. Materials and Methods: In 100 Wistar rats, divided into 5 groups of 20, one of the following medications was used: Acetazolamide liquid (AL); AL with calcium hydroxide powder (ALHC); acetazolamide powder with AL; acetazolamide powder with physiological solution; and calcium hydroxide with physiological solution (control). At 30 and 60 days after reimplantation, the animals were sacrificed, tissues were processed, and cuts were stained with hematoxylin and eosin. An optical microscope was used to determine the following: percentage of inflammatory root resorption (RRI); percentage of substitute root resorption (RRS); and presence of ankylosis. The data obtained was submitted for statistical analysis. Results: Group ALHC had a significantly higher RRS than the control group at 60 days ( P = 0.01). Group AL showed significantly less ankylosis than the other groups, including the control, at 30 days. AL showed results similar to those of the control group with respect to RRS. Conclusion: Acetazolamide has the potential to be an effective intracanal medication. Competing Interests: There are no conflicts of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu